"By the second half of 2008, we expect to have data from two Phase 2 trials in patients with diabetic neuropathy, to have initiated two new trials of SB-509 in stem cell mobilization and ALS, and two new Phase 1 trials in patients with HIV infection and glioblastoma. Achievement of these objectives, as well as commercial progress in our collaboration with Sigma and entry into the commercial phase of our collaboration with Dow AgroSciences, will be key to further enhancing the market-leading presence for our technology. As has become increasingly evident, an innovation gap exists in the pharmaceutical sector, and we believe that our progress in advancing our technology platform, which is unique in its generation of novel, highly differentiated therapies and products, will create interest among potential partners for our ZFP Therapeutic programs."
Sangamo Accomplishments in 2007
During the briefing several of the company's achievements will be
-- Sangamo presented "top-line" clinical data from its ZFP Therapeutic
program to develop SB-509, a ZFP activator of VEGF for the treatment of
diabetic neuropathy at both the Annual Scientific Sessions of the
American Diabetes Association in June and the Society for Neuroscience
Annual Meeting in November. The data showed statistically significant
improvements in several measurements of neurologic health in subjects
with mild to moderate diabetic neuropathy over a six-month period after
treatment with a single administration of SB-509.
-- Sangamo completed accrual for its repeat-dosing Phase 2 trial of SB-509
in patients with mild to moder
|SOURCE Sangamo BioSciences, Inc.|
Copyright©2007 PR Newswire.
All rights reserved